190897-47-3

Basic information

• Product Name: (S)-3-(BOC-AMINO)-2-METHYLPROPIONIC ACID
• Synonyms: Boc-S-3-Aminoisobutyric acid;Propanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-methyl-, (2S)- (9CI);(s)-boc-β2-homoala-oh;2S-METHYL-3-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-PROPANOIC ACID;(S)-3-(tert-ButoxycarbonylaMino)-2-Methylpropanoic acid;Boc-S-3-AMinoisobutyric acid Boc-S-3-AMinoisobutyric acid;Boc-(S)-3-AMino-2-Methylpropanoic acid;(S)-3-(Boc-aMino)-2-Methylpropionic acid
• CAS NO: 190897-47-3
• Molecular Formula: C₉H₁₇NO₄
• Molecular Weight: 203.23558
• Product Categories: N-BOC
• Mol File: 190897-47-3.mol

Chemical Properties

• Melting Point: 88 °C(lit.)
• Boiling Point: 339.502 °C at 760 mmHg
• Flash Point: 159.125 °C
• Appearance: /
• Density: 1.102 g/cm³
• Vapor Pressure: 1.69E-05mmHg at 25°C
• Refractive Index: 1.46
• Storage Temp.: 2-8°C
• PKA: 4.53±0.10(Predicted)
• BRN: 8037279
• CAS DataBase Reference: (S)-3-(BOC-AMINO)-2-METHYLPROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-(BOC-AMINO)-2-METHYLPROPIONIC ACID(190897-47-3)
• EPA Substance Registry System: (S)-3-(BOC-AMINO)-2-METHYLPROPIONIC ACID(190897-47-3)

Safety Data

• WGK Germany: 3
• F: 3-10
• Hazardous Substances Data: 190897-47-3(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C9H17NO4/c1-6(7(11)12)5-10-8(13)14-9(2,3)4/h6H,5H2,1-4H3,(H,10,13)(H,11,12)/t6-/m0/s1

Upstream product

• 374729-55-2 (S)-tert-butyl (2-methyl-3-oxopropyl)carbamate 
• 168828-18-0 methyl (S)-3-(tert-butoxycarbonylamino)-2-methylpropanoate 

Downstream Products

• 144-90-1 (S)-(+)-β²-homoalanine 
• 1345219-32-0 N-(tert-butoxycarbonyl)-α-(S)-methyl-β-alanine benzyl ester 
• 210346-12-6 Boc-β²hAla-β³Leu-OBn 

Relevant articles and documents

Diastereoselective total synthesis and structural confirmation of surugamide F

Surugamide F is a linear decapeptide (1) isolated along with the cyclic octapeptides surugamides A–E (2–6), from a marine-derived Streptomyces species. The linear peptide 1 is produced by two nonribosomal peptide synthetases (NRPSs) encoded in adjacent open reading frames, which are further flanked by an additional pair of NRPS genes responsible for the biosyntheses of the cyclic peptides 2–6. While the cyclic peptides 2–6 were identified to be cathepsin B inhibitors, the biological activity of the new metabolite 1 still remained unclear. In order to elucidate its unique biosynthetic pathway and biological activity in detail, we planned to develop an efficient synthetic route toward 1. Here we report the diastereoselective total synthesis of 1, utilizing 9-fluorenylmethyloxycarbonyl (Fmoc)-based solid-phase peptide synthesis. During this study, we found that the structural correction of 1 was required, due to the mislabeling of the commercially obtained 3-amino-2-methylpropionic acid, and the true structure of 1 was corroborated by the chemical synthesis and chromatographic comparison.

Rhodium-catalyzed asymmetric hydroformylation of n-allvlamides: Highly enantioselective approach to β2-amino aldehydes

(Figure Presented) You're having a lahf I The asymmetric hydroformylation (AHF) of allylic compounds, catalyzed by a rhodium-yanphos complex, is a direct and concise route to ss2-amino aldehydes, acids, and alcohols with excellent enantioselectivity (see scheme; TON =turnover number, acac = acetylacetonate).

NOVEL DIPEPTIDYL PEPTIDASE-IV INHIBITORS

The present invention relates to novel compounds exhibiting excellent inhibitory activity versus Dipeptidyl Peptidase-IV (DPP-IV), methods of preparing the same and pharmaceutical compositions containing the same as an active agent.

ANTITHROMBOTIC ETHERS

This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor (I).

Optical resolution of aminoisobobutyric acid

A process for resolving amino protected racemic 3-amino-2-methylpropionic acid which comprises the steps of: (1) reacting said amino protected acid with a protected amino group with an enantiomer of a chiral amine to form diastereomeric salts; (2) recrystallizing the diastereomeric salts from ethyl acetate to separate the diastereomeric salts into crystal fractions; and (3) releasing the resolved acid from the diastereomeric salt by treating the diastereomeric salt with a basic solution is disclosed. A process for the preparation of the cryptophycin molecules is also disclosed.